Rowville

Researchers are evaluating the effects of ADX-038, a siRNA duplex oligonucleotide, in people with geographic atrophy (GA) caused by age-related macular degeneration (AMD). This Phase 2 study compares ADX-038 with a placebo to assess its ability to preserve the ellipsoid zone (EZ) layer in the eye over 12 months. The study also monitors safety, pharmacokinetics, and pharmacodynamics. Participants will receive subcutaneous injections of either ADX-038 or a saline placebo. The study is randomized, masked, and placebo-controlled, ensuring unbiased comparison between the two groups. The treatment period lasts for 12 months, during which participants will undergo regular clinic visits and follow study procedures. During the study, participants will have eye examinations and imaging to evaluate the condition of the GA lesions and the EZ layer. Researchers will track adherence to study visits and vaccinations required by the protocol. The main goal is to measure the effect of ADX-038 on preserving the EZ layer at 12 months, while monitoring safety and any adverse effects throughout the study.